; Lymphoma - Pipeline Review, Q3 2011
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Lymphoma - Pipeline Review, Q3 2011

VIEWS: 0 PAGES: 672

Lymphoma - Pipeline Review, Q3 2011 Summary Global Markets Direct’s, 'Lymphoma - Pipeline Review, Q3 2011', provides an overview of the Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. 'Lymphoma - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Lymphoma. - A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lymphoma pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Lymphoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers an

More Info
  • pg 1
									Lymphoma – Pipeline Review, Q3 2011




                           Lymphoma - Pipeline Review, Q3 2011
                                                                                          Reference Code: GMDHC1185IDB

                                                                                          Publication Date: July 2011




Lymphoma – Pipeline Review, Q3 2011                                                                                     GMDHC1185IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                      Page(1)
Lymphoma – Pipeline Review, Q3 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                2
List of Tables                                                                                                  23
List of Figures                                                                                                 32
Introduction                                                                                                    33
     Global Markets Direct Report Coverage                                                                      33
Lymphoma Overview                                                                                               34
Therapeutics Development                                                                                        35
     An Overview of Pipeline Products for Lymphoma                                                              35
Lymphoma Therapeutics under Development by Companies                                                            37
Lymphoma Therapeutics under Investigation by Universities/Institutes                                            45
Late Stage Products                                                                                             67
     Comparative Analysis                                                                                       67
Mid Clinical Stage Products                                                                                     68
     Comparative Analysis                                                                                       68
Early Clinical Stage Products                                                                                   69
     Comparative Analysis                                                                                       69
Discovery and Pre-Clinical Stage Products                                                                       70
     Comparative Analysis                                                                                       70
Lymphoma Therapeutics - Products under Development by Companies                                                 71
Lymphoma Therapeutics - Products under Investigation by Universities/Institutes                                 95
Companies Involved in Lymphoma Therapeutics Development                                                        185
     Bristol-Myers Squibb Company                                                                              185
     Genzyme Corporation                                                                                       185
     Johnson & Johnson                                                                                         186
     Boehringer Ingelheim GmbH                                                                                 186
     F. Hoffmann-La Roche Ltd.                                                                                 187
     Kyowa Hakko Kirin Co., Ltd.                                                                               188
     Abbott Laboratories                                                                                       189
     Amgen Inc.                                                                                                189
     Sanofi-Aventis                                                                                            190
     AstraZeneca PLC                                                                                           190
     Eli Lilly and Company                                                                                     191
     GlaxoSmithKline plc                                                                                       191
     Seattle Genetics, Inc.                                                                                    192
     Genentech, Inc.                                                                                           193
     Antigenics, Inc.                                                                                          194
     MMR Information Systems, Inc.                                                                             194
     Biotec Pharmacon ASA                                                                                      195
     MedImmune LLC                                                                                             195
     Gilead Sciences, Inc.                                                                                     196
     Daiichi Sankyo Company, Ltd                                                                               196
     Merck & Co., Inc.                                                                                         197
     AbGenomics International, Inc.                                                                            197
     Emergent BioSolutions Inc.                                                                                198
     Lentigen Corporation                                                                                      198
     Micromet, Inc.                                                                                            199
     Gamida Cell Ltd.                                                                                          199


Lymphoma – Pipeline Review, Q3 2011                                                       GMDHC1185IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(2)
Lymphoma – Pipeline Review, Q3 2011


     Takeda Pharmaceutical Company Limited                                                                     200
     Celltrion, Inc.                                                                                           201
     Bio-Path Holdings, Inc.                                                                                   201
     ZIOPHARM Oncology, Inc.                                                                                   202
     Novartis AG                                                                                               202
     Astellas Pharma Inc.                                                                                      203
     Biocon Limited                                                                                            203
     BioMarin Pharmaceutical Inc.                                                                              204
     Cephalon, Inc.                                                                                            204
     Dong-A Pharmaceutical Co., Ltd.                                                                           205
     Eisai Co., Ltd.                                                                                           206
     Genta Incorporated                                                                                        206
     Human Genome Sciences, Inc.                                                                               207
     ImmunoGen, Inc.                                                                                           207
     OSI Pharmaceuticals, Inc.                                                                                 208
     Pfizer Inc.                                                                                               208
     Sunesis Pharmaceuticals, Inc.                                                                             209
     SuperGen, Inc.                                                                                            209
     Cell Therapeutics, Inc.                                                                                   210
     Genmab A/S                                                                                                210
     Santaris Pharma A/S                                                                                       211
     Astex Therapeutics Limited                                                                                211
     Cyclacel Pharmaceuticals Inc.                                                                             212
     Alfacell Corporation                                                                                      212
     Celgene Corporation                                                                                       213
     Onyx Pharmaceuticals, Inc.                                                                                213
     Bayer AG                                                                                                  214
     Geron Corporation                                                                                         215
     Merck KGaA                                                                                                215
     4SC AG                                                                                                    216
     Hana Biosciences, Inc.                                                                                    216
     Celldex Therapeutics, Inc.                                                                                217
     AEterna Zentaris Inc.                                                                                     217
     IMMUNOMEDICS, INC                                                                                         218
     InNexus Biotechnology Inc.                                                                                218
     Idera Pharmaceuticals, Inc.                                                                               219
     Ariad Pharmaceuticals, Inc.                                                                               219
     MethylGene Inc                                                                                            220
     NexMed, Inc.                                                                                              220
     Northwest Biotherapeutics, Inc.                                                                           221
     Cleveland BioLabs, Inc.                                                                                   221
     Accentia Biopharmaceuticals, Inc.                                                                         222
     Keryx Biopharmaceuticals, Inc.                                                                            222
     Allos Therapeutics, Inc                                                                                   223
     BioCryst Pharmaceuticals, Inc.                                                                            223
     Portola Pharmaceuticals, Inc.                                                                             224
     Cytokinetics, Inc                                                                                         224
     Telik, Inc.                                                                                               225




Lymphoma – Pipeline Review, Q3 2011                                                       GMDHC1185IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(3)
Lymphoma – Pipeline Review, Q3 2011


     TopoTarget A/S                                                                                            225
     Mundipharma International Limited                                                                         226
     Pharmacyclics, Inc.                                                                                       226
     Dendreon Corporation                                                                                      227
     MorphoSys AG                                                                                              227
     Progen Pharmaceuticals Limited                                                                            228
     Green Cross Corporation                                                                                   228
     LG Life Sciences, Ltd                                                                                     229
     Synta Pharmaceuticals Corp.                                                                               229
     CrystalGenomics, Inc.                                                                                     230
     Sareum Holdings plc                                                                                       230
     Innate Pharma SA                                                                                          231
     Piramal Life Sciences Limited                                                                             231
     SymBio Pharmaceuticals Limited                                                                            232
     Arthur G. James Cancer Hospital & Richard J. Solove Research Institute                                    232
     Baylor College of Medicine                                                                                233
     Digna Biotech, S.L.                                                                                       234
     Spectrum Pharmaceuticals, Inc.                                                                            235
     Debiopharm Group                                                                                          235
     Affimed Therapeutics AG                                                                                   236
     Chipscreen Biosciences Ltd                                                                                236
     Ambit Biosciences Corporation                                                                             237
     Memgen, LLC.                                                                                              237
     Philogen S.p.A.                                                                                           237
     PanGenetics B.V.                                                                                          238
     Abiogen Pharma S.p.A.                                                                                     238
     Multimmune GmbH                                                                                           238
     TRION Pharma GmbH                                                                                         239
     MAT Biopharma                                                                                             239
     Aquinox Pharmaceuticals Inc.                                                                              240
     Biolex Therapeutics, Inc.                                                                                 240
     AgrenVec, S.L.                                                                                            241
     Ascenta Therapeutics, Inc.                                                                                241
     Cerulean Pharma, Inc.                                                                                     241
     Provenance Biopharmaceuticals Corp.                                                                       242
     Pharmascience Inc.                                                                                        242
     Arno Therapeutics, Inc.                                                                                   243
     TetraLogic Pharmaceuticals                                                                                243
     Unibioscreen S.A.                                                                                         243
     Celentyx Ltd.                                                                                             244
     Semafore Pharmaceuticals, Inc.                                                                            244
     S*BIO Pte Ltd                                                                                             245
     ProNAi Therapeutics, Inc.                                                                                 245
     Jennerex Biotherapeutics, Inc.                                                                            245
     Synageva BioPharma Corp.                                                                                  246
     Avila Therapeutics, Inc.                                                                                  246
     Yaupon Therapeutics, Inc.                                                                                 247
     Onconova Therapeutics, Inc                                                                                247




Lymphoma – Pipeline Review, Q3 2011                                                       GMDHC1185IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(4)
Lymphoma – Pipeline Review, Q3 2011


     TcL Pharma SAS                                                                                            248
     Immune System Therapeutics Ltd.                                                                           248
     Intellikine, Inc.                                                                                         248
     Syndax Pharmaceuticals, Inc.                                                                              249
     Myriad Pharmaceuticals, Inc.                                                                              249
     Morphogenesis, Inc.                                                                                       250
     Xencor, Inc.                                                                                              250
     Drais Pharmaceuticals, Inc.                                                                               251
     PharmaMar, S.A.                                                                                           251
     Bellicum Pharmaceuticals, Inc.                                                                            251
     VentiRx Pharmaceuticals, Inc.                                                                             252
     Kinex Pharmaceuticals, LLC                                                                                252
     Prospect Therapeutics, Inc.                                                                               253
     CureTech Ltd.                                                                                             253
     Cylene Pharmaceuticals, Inc.                                                                              253
     GlycoMimetics, Inc.                                                                                       254
     Hy BioPharma Inc.                                                                                         254
     Nereus Pharmaceuticals, Inc.                                                                              255
     AVEO Pharmaceuticals, Inc.                                                                                255
     Archer Biosciences, Inc                                                                                   255
     Averion, Inc.                                                                                             256
     Zenyaku Kogyo Co., Ltd.                                                                                   256
     Mebiopharm Co., Ltd.                                                                                      256
     Polaris Group                                                                                             257
     Probiomed S.A. de C.V.                                                                                    257
     Theradex Systems, Inc.                                                                                    258
     ImQuest Life Sciences                                                                                     258
     Immunovative Therapies, Ltd.                                                                              258
     Laboratoire français de Fractionnement et de Biotechnologies                                              259
     American Scitech Inc.                                                                                     259
     PharmaTech International, Inc.                                                                            260
     Pharmatech Oncology, Inc                                                                                  260
Lymphoma - Therapeutics Assessment                                                                             261
     Assessment by Monotherapy Products                                                                        261
     Assessment by Combination Products                                                                        262
     Assessment by Route of Administration                                                                     263
     Assessment by Molecule Type                                                                               266
Late Stage Drug Profiles                                                                                       269
     StemEx - Drug Profile                                                                                     269
          Product Description                                                                                  269
          Mechanism of Action                                                                                  269
          R&D Progress                                                                                         269
     RG7159 - Drug Profile                                                                                     270
          Product Description                                                                                  270
          Mechanism of Action                                                                                  270
          R&D Progress                                                                                         270
     Enzastaurin - Drug Profile                                                                                271
          Product Description                                                                                  271




Lymphoma – Pipeline Review, Q3 2011                                                       GMDHC1185IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(5)
Lymphoma – Pipeline Review, Q3 2011


          Mechanism of Action                                                                                  271
          R&D Progress                                                                                         271
     MAbThera - Drug Profile                                                                                   272
          Product Description                                                                                  272
          Mechanism of Action                                                                                  272
          R&D Progress                                                                                         272
     MAbThera - Drug Profile                                                                                   274
          Product Description                                                                                  274
          Mechanism of Action                                                                                  274
          R&D Progress                                                                                         274
     Adcetris - Drug Profile                                                                                   276
          Product Description                                                                                  276
          Mechanism of Action                                                                                  276
          R&D Progress                                                                                         276
     Arzerra - Drug Profile                                                                                    278
          Product Description                                                                                  278
          Mechanism of Action                                                                                  278
          R&D Progress                                                                                         278
     LBH589 - Drug Profile                                                                                     281
          Product Description                                                                                  281
          Mechanism of Action                                                                                  281
          R&D Progress                                                                                         281
     BiovaxID - Drug Profile                                                                                   283
          Product Description                                                                                  283
          Mechanism of Action                                                                                  283
          R&D Progress                                                                                         283
     Pixantrone - Drug Profile                                                                                 284
          Product Description                                                                                  284
          Mechanism of Action                                                                                  284
          R&D Progress                                                                                         284
     Velcade - Drug Profile                                                                                    286
          Product Description                                                                                  286
          Mechanism of Action                                                                                  286
          R&D Progress                                                                                         286
     Afinitor - Drug Profile                                                                                   287
          Product Description                                                                                  287
          Mechanism of Action                                                                                  287
          R&D Progress                                                                                         287
     KW-0761 - Drug Profile                                                                                    289
          Product Description                                                                                  289
          Mechanism of Action                                                                                  289
          R&D Progress                                                                                         289
     SyB L-0501 - Drug Profile                                                                                 290
          Product Description                                                                                  290
          Mechanism of Action                                                                                  290
          R&D Progress                                                                                         290
     Forodesine - Drug Profile                                                                                 292
          Product Description                                                                                  292




Lymphoma – Pipeline Review, Q3 2011                                                       GMDHC1185IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(6)
Lymphoma – Pipeline Review, Q3 2011


          Mechanism of Action                                                                                     292
          R&D Progress                                                                                            292
     Clearazide - Drug Profile                                                                                    294
          Product Description                                                                                     294
          Mechanism of Action                                                                                     294
          R&D Progress                                                                                            294
     Folotyn - Drug Profile                                                                                       295
          Product Description                                                                                     295
          Mechanism of Action                                                                                     295
          R&D Progress                                                                                            295
     HuMax-CD4 - Drug Profile                                                                                     297
          Product Description                                                                                     297
          Mechanism of Action                                                                                     297
          R&D Progress                                                                                            297
     Epratuzumab - Drug Profile                                                                                   299
          Product Description                                                                                     299
          Mechanism of Action                                                                                     299
          R&D Progress                                                                                            299
     Voriconazole - Drug Profile                                                                                  300
          Product Description                                                                                     300
          Mechanism of Action                                                                                     300
          R&D Progress                                                                                            300
     Adriamycin + Bleomycin + Vincristine + Dacarbazine + Radiation Therapy - Drug Profile                        301
          Product Description                                                                                     301
          Mechanism of Action                                                                                     301
          R&D Progress                                                                                            301
     Rituximab + Fludarabine + Cyclophosphamide - Drug Profile                                                    303
          Product Description                                                                                     303
          Mechanism of Action                                                                                     303
          R&D Progress                                                                                            303
     Busulfan + Cyclophosphamide - Drug Profile                                                                   304
          Product Description                                                                                     304
          Mechanism of Action                                                                                     304
          R&D Progress                                                                                            304
     Fludarabine phosphate + Melphalan - Drug Profile                                                             305
          Product Description                                                                                     305
          Mechanism of Action                                                                                     305
          R&D Progress                                                                                            305
     Cyclophosphamide + Etoposide + Total Body Irradiation - Drug Profile                                         306
          Product Description                                                                                     306
          Mechanism of Action                                                                                     306
          R&D Progress                                                                                            306
     Carboplatin + Thiotepa + Cyclophosphamide - Drug Profile                                                     307
          Product Description                                                                                     307
          Mechanism of Action                                                                                     307
          R&D Progress                                                                                            307
     Allopurinol - Drug Profile                                                                                   308
          Product Description                                                                                     308




Lymphoma – Pipeline Review, Q3 2011                                                          GMDHC1185IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(7)
Lymphoma – Pipeline Review, Q3 2011


          Mechanism of Action                                                                                  308
          R&D Progress                                                                                         308
     Rasburicase - Drug Profile                                                                                309
          Product Description                                                                                  309
          Mechanism of Action                                                                                  309
          R&D Progress                                                                                         309
     Fludarabine phosphate + Anti-thymocyte globulin - Drug Profile                                            310
          Product Description                                                                                  310
          Mechanism of Action                                                                                  310
          R&D Progress                                                                                         310
     Bendamustine + Rituximab - Drug Profile                                                                   311
          Product Description                                                                                  311
          Mechanism of Action                                                                                  311
          R&D Progress                                                                                         311
     fludarabine phosphate - Drug Profile                                                                      312
          Product Description                                                                                  312
          Mechanism of Action                                                                                  312
          R&D Progress                                                                                         312
     Cyclophosphamide + Epirubicin + Vincristine + Prednisone - Drug Profile                                   313
          Product Description                                                                                  313
          Mechanism of Action                                                                                  313
          R&D Progress                                                                                         313
     Rituximab + Chlorambucil - Drug Profile                                                                   314
          Product Description                                                                                  314
          Mechanism of Action                                                                                  314
          R&D Progress                                                                                         314
     Rituximab - Drug Profile                                                                                  315
          Product Description                                                                                  315
          Mechanism of Action                                                                                  315
          R&D Progress                                                                                         315
     Chlorambucil - Drug Profile                                                                               316
          Product Description                                                                                  316
          Mechanism of Action                                                                                  316
          R&D Progress                                                                                         316
     Mitoxantrone + Chlorambucil + Dexamethasone - Drug Profile                                                317
          Product Description                                                                                  317
          Mechanism of Action                                                                                  317
          R&D Progress                                                                                         317
     Mitoxantrone + Dexamethasone + Fludarabine - Drug Profile                                                 319
          Product Description                                                                                  319
          Mechanism of Action                                                                                  319
          R&D Progress                                                                                         319
     Chlorambucil - Drug Profile                                                                               321
          Product Description                                                                                  321
          Mechanism of Action                                                                                  321
          R&D Progress                                                                                         321
     Fludarabine Phosphate - Drug Profile                                                                      322
          Product Description                                                                                  322




Lymphoma – Pipeline Review, Q3 2011                                                       GMDHC1185IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(8)
Lymphoma – Pipeline Review, Q3 2011


          Mechanism of Action                                                                                  322
          R&D Progress                                                                                         322
     Chlorambucil For Follicular lymphoma - Drug Profile                                                       323
          Product Description                                                                                  323
          Mechanism of Action                                                                                  323
          R&D Progress                                                                                         323
     ondansetron - Drug Profile                                                                                324
          Product Description                                                                                  324
          Mechanism of Action                                                                                  324
          R&D Progress                                                                                         324
     Velcade + Rituximab - Drug Profile                                                                        325
          Product Description                                                                                  325
          Mechanism of Action                                                                                  325
          R&D Progress                                                                                         325
     CMC-544 - Drug Profile                                                                                    326
          Product Description                                                                                  326
          Mechanism of Action                                                                                  326
          R&D Progress                                                                                         326
     CMC-544 + Rituxan - Drug Profile                                                                          327
          Product Description                                                                                  327
          Mechanism of Action                                                                                  327
          R&D Progress                                                                                         327
     SDX-105 + Rituxan - Drug Profile                                                                          328
          Product Description                                                                                  328
          Mechanism of Action                                                                                  328
          R&D Progress                                                                                         328
     Revlimid - Drug Profile                                                                                   329
          Product Description                                                                                  329
          Mechanism of Action                                                                                  329
          R&D Progress                                                                                         329
     R05072759 + Bendamustine - Drug Profile                                                                   331
          Product Description                                                                                  331
          Mechanism of Action                                                                                  331
          R&D Progress                                                                                         331
     Arzerra + Bendamustine - Drug Profile                                                                     332
          Product Description                                                                                  332
          Mechanism of Action                                                                                  332
          R&D Progress                                                                                         332
     Pixantrone + Rituximab + Fludarabine - Drug Profile                                                       334
          Product Description                                                                                  334
          Mechanism of Action                                                                                  334
          R&D Progress                                                                                         334
     Pixantrone + Rituximab - Drug Profile                                                                     336
          Product Description                                                                                  336
          Mechanism of Action                                                                                  336
          R&D Progress                                                                                         336
     Avastin + R-CHOP - Drug Profile                                                                           337
          Product Description                                                                                  337




Lymphoma – Pipeline Review, Q3 2011                                                       GMDHC1185IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(9)
Lymphoma – Pipeline Review, Q3 2011


          Mechanism of Action                                                                                                          337
          R&D Progress                                                                                                                 338
     Fludarabine + Mitoxantrone + Dexamethasone + Rituximab - Drug Profile                                                             339
          Product Description                                                                                                          339
          Mechanism of Action                                                                                                          339
          R&D Progress                                                                                                                 339
     filgrastim + rituximab + carboplatin + etoposide + ifosfamide - Drug Profile                                                      341
          Product Description                                                                                                          341
          Mechanism of Action                                                                                                          341
   
								
To top